Affirmed Therapeutics BV Company Profile (NASDAQ:AFMD)

Analyst Ratings

Consensus Ratings for Affirmed Therapeutics BV (NASDAQ:AFMD) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $10.60 (277.22% upside)

Analysts' Ratings History for Affirmed Therapeutics BV (NASDAQ:AFMD)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016Leerink SwannUpgradeMarket Perform -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Jefferies GroupLower Price TargetHold -> Hold$5.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/10/2015LaidlawInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/20/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Affirmed Therapeutics BV (NASDAQ:AFMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/18/2016Q116($0.17)($0.25)$1.88 million$1.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2016Q415($0.18)($0.22)$1.71 million$1.66 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.25)($0.24)$1.87 million$1.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.14)($0.21)$2.56 million$2.21 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/21/2015Q115($0.14)($0.07)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2015Q414($0.33)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/18/2014Q314($0.33)$2.69ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Affirmed Therapeutics BV (NASDAQ:AFMD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.28)($0.28)($0.28)
Q2 20162($0.29)($0.14)($0.22)
Q3 20162($0.29)($0.23)($0.26)
Q4 20163($0.31)($0.19)($0.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Affirmed Therapeutics BV (NASDAQ:AFMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Affirmed Therapeutics BV (NASDAQ:AFMD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Affirmed Therapeutics BV (NASDAQ:AFMD)
DateHeadline
06/30/16 02:23 PMAffimed N.V. (NASDAQ:AFMD) Earnings Glance and Target Price Review - Engelwood Daily
06/29/16 02:19 PMAffimed NV (NASDAQ: AFMD) Set To Develop Clinical Candidate is AFM13 - Scibility Media
06/27/16 07:07 AMStrong Sell Calls Recommendations For Affimed N.V. (NASDAQ:AFMD) At 0 - Investor Newswire
06/23/16 09:47 PMAffimed NV (NASDAQ:AFMD) Earnings Glance and Target Price Review - Engelwood Daily
06/22/16 02:20 PMAffimed NV (NasdaqGM:AFMD) Stock Momentum Hits EXTREME Weakness - CML News
06/20/16 08:52 AMStrong Buy Calls Count For Affimed N.V. (NASDAQ:AFMD) At 3 - Investor Newswire
06/12/16 07:40 PMTrend Of Rating Given To Affimed N.V. (NASDAQ:AFMD) - Investor Newswire
06/10/16 02:23 PMAffimed N.V. (NASDAQ:AFMD) Dropped-9.07%: Verizon Communications Inc. (NYSE:VZ), Del Frisco's Restaurant ... - KC Register
06/03/16 10:50 AMStock Review and Earnings Check on Affimed N.V. (NASDAQ:AFMD) - HNN
06/03/16 06:55 AMThese 7 Stocks Under $10 Are About to Break Out -
06/01/16 02:23 PMTarget Price and Stock Performance Rundown for Affimed N.V. (NASDAQ:AFMD) - HNN - Target Price and Stock Performance Rundown for Affimed N.V. (NASDAQ:AFMD)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Affimed N.V. (NASDAQ:AFMD) shares ...and more »
06/01/16 10:42 AMAffimed N.V. (NASDAQ:AFMD) Stock Update & Estimates - Stock Tick Tock - Affimed N.V. (NASDAQ:AFMD) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Affimed N.V. (NASDAQ:AFMD) to post earnings of $-0.19 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...Affimed NV (NASDAQ:AFMD) Given Average Rating of “Buy” by AnalystsLet Me Know About ThisAffimed Therapeutics B.V. (AFMD) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsAffimed Therapeutics B.V. (AFMD) Updated Analyst CoverageRisers & FallersThe Postall 5 news articles »
05/31/16 04:22 AMAffimed to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - 9920686b-620e-47c7-afed-8bf25a6133cc.pdf FOR IMMEDIATE RELEASE Heidelberg, Germany, May 31, 2016 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing ...
05/30/16 08:52 PMAffimed NV (NASDAQ:AFMD) Given Average Rating of “Buy” by Analysts - Let Me Know About This - Affimed NV (NASDAQ:AFMD) Given Average Rating of “Buy” by AnalystsLet Me Know About ThisAffimed NV logo Affimed NV (NASDAQ:AFMD) has been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the firm. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the ...Were Analysts Bullish Affimed NV (NASDAQ:AFMD) This Week?The Postall 2 news articles »
05/28/16 01:46 PMEarnings Review and Stock Rundown for Affimed N.V. (NASDAQ:AFMD) - Wall Street Hints and News - Earnings Review and Stock Rundown for Affimed N.V. (NASDAQ:AFMD)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Affimed N.V. (NASDAQ:AFMD) to post ...and more »
05/26/16 01:50 PMLeerink Swann Downgrades Affimed NV to Market Perform - Trade Calls - Leerink Swann Downgrades Affimed NV to Market PerformTrade CallsBrokerage firm Leerink Swann Downgrades its rating on Affimed NV(NASDAQ:AFMD). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by Leerink Swann was issued on May 19, 2016.and more »
05/24/16 03:16 AMAffimed Announces Annual General Meeting of Shareholders - [at noodls] - 772a9ea1-1564-49d6-8952-980125a36277.pdf FOR IMMEDIATE RELEASE Heidelberg, Germany, May 23, 2016 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing ...
05/19/16 08:17 AMAffimed Therapeutics downgraded by Leerink Partners -
05/18/16 06:52 AMAffimed Reports Financial Results for First Quarter 2016 - [at noodls] - dd17b5c9-1668-4e8a-8220-305f6edb6bdd.pdf FOR IMMEDIATE RELEASE Heidelberg, Germany, May 18, 2016 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing ...
05/18/16 06:07 AMQ1 2016 Affimed NV Earnings Release - Time Not Supplied -
05/17/16 04:00 AMAffimed to Present at the UBS Global Healthcare Conference -- New York - [GlobeNewswire] - HEIDELBERG, Germany -- Affimed today announced that Dr. Adi Hoess, CEO, will present a corporate overview at the UBS Global Healthcare Conference -- New York, to be held May 23-25, 2016.
05/11/16 04:22 AMAffimed Announces First Quarter 2016 Financial Results and Corporate Update Conference Call - [at noodls] - 2cf31aeb-e05e-4b00-b747-cb68cd6fa260.pdf FOR IMMEDIATE RELEASE Heidelberg, Germany, May 11, 2016 - Affimed N.V. (Nasdaq: AFMD) today announced that on May 18, 2016, the Company will release its financial ...
05/05/16 03:48 PMETF’s with exposure to Affimed NV : May 5, 2016 -
04/21/16 04:17 AMAffimed Presents Data on EGFRwt and EGFRvIII-targeting NK- and T-Cell TandAbs at the AACR Annual Meeting 2016 - [at noodls] - b1ec93dd-cdb2-4cee-8af7-d8e41d2b9c8c.pdf FOR IMMEDIATE RELEASE Heidelberg, Germany, April 21, 2016 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing ...
04/21/16 04:17 AMAffimed Presents Data on AFM13-mediated Innate/Adaptive Immune Crosstalk at the AACR Annual Meeting 2016 - [at noodls] - a60fbbe4-0dab-4c30-93c6-5689f7734511.pdf FOR IMMEDIATE RELEASE Heidelberg, Germany, April 21, 2016 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing ...
03/31/16 07:32 PMAffimed NV (AFMD): Samuel Isaly Unloads Shares of Sinking Stock -
02/26/16 11:52 AMAre Analysts Bearish Affimed NV (NASDAQ:AFMD) After Last Week? - RiversideGazette.com - Are Analysts Bearish Affimed NV (NASDAQ:AFMD) After Last Week?RiversideGazette.comOut of 4 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 4 rate it “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Affimed Therapeutics was the topic in 9 analyst reports since August 6, 2015 according to StockzIntelligence Inc ...
02/22/16 04:00 AMAffimed to Speak at Symposium on Emerging Approaches in Cancer Immunotherapy - [GlobeNewswire] - HEIDELBERG, Germany -- Affimed N.V. , a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that its CMO, Jens-Peter Marschner, ...
02/14/16 01:25 PMAffimed NV (NASDAQ:AFMD) Shorted Shares Increased 28.98% After Market Selling - fdanewsalert.com - Affimed NV (NASDAQ:AFMD) Shorted Shares Increased 28.98% After Market Sellingfdanewsalert.comThe stock of Affimed NV (NASDAQ:AFMD) registered an increase of 28.98% in short interest. AFMD's total short interest was 1.61 million shares in February as published by FINRA. Its up 28.98% from 1.25 million shares, reported previously. With 732,900 ...
02/05/16 01:35 PMAffimed NV (NASDAQ:AFMD) Shorted Shares Increased By 26.79% - fdanewsalert.com - CWRU ObserverAffimed NV (NASDAQ:AFMD) Shorted Shares Increased By 26.79%fdanewsalert.comThe stock of Affimed NV (NASDAQ:AFMD) registered an increase of 26.79% in short interest. AFMD's total short interest was 1.25 million shares in February as published by FINRA. Its up 26.79% from 986,500 shares, reported previously. With 417,900 shares ...Analytical Approach to Watch for: Affimed NVCWRU Observerall 2 news articles »
02/04/16 01:30 PMAffimed N.V. (NASDAQ:AFMD): Quarterly Earnings Update - Investor Newswire - Affimed N.V. (NASDAQ:AFMD): Quarterly Earnings UpdateInvestor NewswireAs per the research firms that were included in Zacks Research survey, Affimed N.V. (NASDAQ:AFMD) is projected an EPS of $-0.22 for last quarter. The firm can release the earnings report on or around 2016-03-23. Since the ratings compiled by Zacks ...and more »
02/04/16 04:00 AMAffimed to Present at the Leerink Partners 5th Annual Global Healthcare Conference - [GlobeNewswire] - HEIDELBERG, Germany -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi ...
01/30/16 12:38 PMAffimed N.V. (NASDAQ:AFMD) Analyst Rating Update - Investor Newswire - Affimed N.V. (NASDAQ:AFMD) Analyst Rating UpdateInvestor NewswireWall Street analysts polled by Zacks Research have given Affimed N.V. (NASDAQ:AFMD) a rating of 1.5 on a consensus basis. Using a simplified scale where 1 is a Strong Buy and 5 a Strong Sell, this is the average number of the 3 brokerages surveyed.
01/28/16 12:51 PMAffimed N.V. (NASDAQ:AFMD) Short Interest Update - WallStreet Prudent - Affimed N.V. (NASDAQ:AFMD) Short Interest UpdateWallStreet PrudentAffimed N.V. (NASDAQ:AFMD) reported a rise of 26.8% or 264,295 shares in its short interest. The short figure came in at 6.9% of the total floats. The average daily volume of 417,856 shares suggests that the days to cover 1,250,764 short positions, as ...
01/24/16 06:36 PMCompany Shares of Affimed NV (NASDAQ:AFMD) Rally 1.65% - WallStreet Prudent - Company Shares of Affimed NV (NASDAQ:AFMD) Rally 1.65%WallStreet PrudentShares of Affimed N.V. (NASDAQ:AFMD) appreciated by 1.65% during the past week but lost 49.93% on a 4-week basis. The shares have outperformed the S&P 500 by 0.23% in the past week but underperformed the index by 45.89% in the last 4 weeks.
01/21/16 09:06 AMAffimed Appoints Dr. Joerg Windisch as Chief Operating Officer and Adds Dr. Bernhard Ehmer to Supervisory Board - [at noodls] - 7f55322b-374c-4cb7-b902-5cd01e7ee216.pdf FOR IMMEDIATE RELEASE Heidelberg, Germany, January 21, 2016 -­ Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and ...
01/21/16 09:00 AM10:00 am Affimed Therapeutics names Dr. Joerg Windisch as COO -
01/20/16 04:25 AMAffimed to Host Hodgkin’s Lymphoma Day with Key Opinion Leaders on January 26th in New York - [at noodls] - Microsoft Word - afmd_hl kol day announcement_final (2).docx FOR IMMEDIATE RELEASE Affimed to Host Hodgkin's Lymphoma Day with Key Opinion Leaders on January 26th in New York City Heidelberg, Germany, ...
01/20/16 04:00 AMAffimed to Host Hodgkin's Lymphoma Day with Key Opinion Leaders on January 26th in New York City - [GlobeNewswire] - HEIDELBERG, Germany -- Affimed N.V. , a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that the Company will host ...
01/18/16 06:39 PMAffimed N.V. (NASDAQ:AFMD) - Stock Sentiment And ABR Update - Investor Newswire - Affimed N.V. (NASDAQ:AFMD) - Stock Sentiment And ABR UpdateInvestor NewswireZacks Research has given an average broker rating of 1.5 to Affimed N.V. (NASDAQ:AFMD)'s shares. Zacks assigns a simplified score in between one and five against the complex analysts' ratings. A score towards 1-2 typically means a consensus Buy, ...and more »
01/18/16 11:12 AMAnalysts Review: Affimed NV - iStreetWire - Analysts Review: Affimed NViStreetWireAffimed NV (AFMD) on January 14, 2016 announced that Dr. Andrew Evens has joined Affimed's Scientific Advisory Board. Dr. Evens is Professor of Medicine at Tufts University School of Medicine and he is Chief of the Division of Hematology/Oncology and ...
01/12/16 04:30 AMAffimed to Present at Noble Financial Capital Markets’ 12th Annual Investor Conference - [at noodls] - 8ee3979d-38b8-4e0b-94c1-1b668a4e7dd6.pdf FOR IMMEDIATE RELEASE Affimed to Present at Noble Financial Capital Markets' 12th Annual Investor Conference Heidelberg, Germany, January 12, 2016 - Affimed N.V. ...
01/12/16 04:00 AMAffimed to Present at Noble Financial Capital Markets' 12th Annual Investor Conference - [GlobeNewswire] - HEIDELBERG, Germany -- Affimed N.V. , a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that its CFO, Florian Fischer, ...
12/28/15 07:46 AMWhy You Shouldn't Bet Against Affimed (AFMD) Stock -
12/23/15 08:22 AMAffimed NV Earnings Analysis: Q3, 2015 By the Numbers -
12/14/15 04:17 AMAffimed Added to NASDAQ Biotech Index - [at noodls] - 57a0071b-85b4-4f59-af09-5e1fd860502e.pdf FOR IMMEDIATE RELEASE ® Heidelberg, Germany, December 14, 2015 -­ Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering ...
12/14/15 04:00 AMAffimed Added to NASDAQ Biotech Index® - [GlobeNewswire] - HEIDELBERG, Germany, Dec. 14, 2015-- Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that the Company ...
12/08/15 12:08 PMAFFIMED N.V. Financials -
12/08/15 07:00 AMWhy Biotech Affimed N.V. Should Be On Your Radar -
12/06/15 08:29 AMAffimed Presents Data Comparing T-cell- and NK-cell-engaging TandAbs AFM11 and AFM12 at ASH - [at noodls] - 5d9ca5c6-20a0-49ed-8e66-b92ff06fe337.pdf FOR IMMEDIATE RELEASE Affimed Presents Data Comparing T-­cell-­ and NK-­cell-­ engaging TandAbs AFM11 and AFM12 at ASH -­-­ Differentiated Product Profiles Provide ...

Social

About Affirmed Therapeutics BV

Affirmed Therapeutics BV logoAffimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AFMD
  • CUSIP:
Key Metrics:
  • Previous Close: $2.79
  • 50 Day Moving Average: $2.98
  • 200 Day Moving Average: $3.59
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $95.11M
  • Beta: 3.8
  • Current Year EPS Consensus Estimate: $-1.04 EPS
  • Next Year EPS Consensus Estimate: $-1.11 EPS
Additional Links:
Affirmed Therapeutics BV (NASDAQ:AFMD) Chart for Monday, July, 25, 2016